E. C. Borden

Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.

D. Reding, E. Borden, T. Mcauliffe, 1993, Cancer research.

Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma.

T. Merigan, S. Horning, E. Borden, 1984, The American journal of medicine.

Low doses of interferon alpha result in more effective clinical natural killer cell activation.

B. Edwards, E. Borden, R. Fuhlbrigge, 1985, The Journal of clinical investigation.

Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.

S. Ramanujam, E. Borden, R. Truitt, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial.

E. Borden, J. Gutterman, J. Holland, 1982, Annals of internal medicine.

Isoforms p69 and p100 of 2',5'-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro.

E. Borden, A. Hovanessian, P. Witt, 1993, Journal of interferon research.